has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens subcutaneous route therapeutic vaccine function vaccine in clinical trial role therapeutic cancer vaccine whole cell cancer vaccine neoantigen-loaded autologous dendritic cell vaccine cancer vaccine NCT: https://clinicaltrials.gov/study/NCT03871205 Hayleigh Kahn NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C141422 NCT: https://clinicaltrials.gov/study/NCT04147078 A cancer vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM). NCT: https://clinicaltrials.gov/study/NCT04912765] NCT: https://clinicaltrials.gov/study/NCT03674073 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6281 6281 Jie Zheng